INmune Bio Inc. (NASDAQ:INMB) will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.inmunebio.com
Earnings Expectation
INmune Bio Inc. is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, INMB to report 3Q20 loss of $ 0.17 per share. For the full year, analysts anticipate loss of $ 0.75 per share bottom line.
INmune Bio Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patients innate immune system to treat cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood; and XPro1595 for the treatment of Alzheimers disease.
